ALBA Synchrotron
Synchrotron light to investigate new plant-based vesicular delivery systems
Nanomol Technologies is a GMP certified pharmaceutical laboratory delivering solutions to process, formulate and characterize, at micro and nanoscale, active molecules of pharma, biotech and healthcare companies. Their mission is to provide revolutionary nanomedicines and drug delivery systems with outstanding therapeutic efficacy and patient's compliance.
In their experiments at ALBA, Nanomol Technologies aimed to investigate, at the nanometre scale, a new platform of nanovesicles recently developed based on vegetal sterols and sugar-based surfactants using proprietary DELOS technology (EP patent filed in August 2022, besides granted procedure patents). These new vesicular delivery systems are composed of β-Sitosterol (Sit), Lauryl Glucoside (LGL) and Lauryl Glucose Carboxylate (LGC) molecules, all plant-based, biodegradable and biocompatible components.
Nanomol used ALBA's small angle X-ray scattering (SAXS) beamline, NCD-SWEET, which can study structures in the 1-100 nm range. Here, analysis was performed to study the multi-lamellarity and cross-sectional structure of the nanovesicles, which allowed the characterization and classification of some promising formulations.
The data collected at NCD-SWEET aided in the development of the new plant-based nanovesicles that can successfully function as topical delivery systems, with clear application in the pharmaceutical and healthcare industries (see Alcaina-Hernando, M., et al. (2024)).
Goals of the research
- Develop plant-based nanovesicles for drug delivery
Instruments used
Figure at the left shows SAXS data plotted in log-log scale, the experimental data as symbols and the model as continuous curves. Figure at the right is the legend, naming the relevant formulations.
This investigation was possible thanks to TamaTA-INNOV, a programme of the European project LEAPS-INNOV, which granted access to Nanomol Technologies to perform their studies at ALBA. This project has received funding from European Union's Horizon 2020 research and innovation programme under grant agreement No. 101004728.
